Long-acting galenical formulation for GRF peptides
US5817627A · kind A · utility
1Cited by
13References
4Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 14, 1996 |
| Grant date | Oct 6, 1998 |
| Priority date | — |
| Expiry date | Jun 14, 2016 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/25
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to a long-acting galenical formulation of GRF peptides, pro-GRF and/or analogs thereof which comprises about 1 to about 100 mg of a GRF peptide, fragment or analog thereof pressed from about 1 to about 100 kg/mm.sup.2 in a tablet for parenteral administration, whereby these GRF peptides are released as the tablet is eroded.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.